Dermorphin
Immune & Anti-InflammatoryAlso known as: Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2, Frog Opioid Peptide
Mechanism
Dermorphin is an extraordinarily potent natural pain-relieving peptide originally discovered in the skin of South American tree frogs. It is 30-40 times more potent than morphine by weight and has extremely high selectivity for mu-opioid receptors — the same receptors that morphine and other opioid painkillers target. Its unique feature is a D-amino acid at position 2, which is almost never found in animal peptides and makes it highly resistant to enzymatic breakdown. It is used primarily as a research tool for studying opioid receptor pharmacology.
Technical detail
Dermorphin (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) is a naturally occurring heptapeptide isolated from skin secretions of Phyllomedusa frogs (discovered by Erspamer, 1981). It is one of the most potent naturally occurring mu-opioid receptor (MOR) agonists known, with 100-fold higher binding affinity than morphine (Kd ~0.46 nM). The D-Ala at position 2 is critical for MOR binding and confers exceptional resistance to peptidase degradation. The N-terminal Tyr-D-Ala-Phe sequence constitutes the 'message' pharmacophore. Activates two MOR subtypes in the CNS: spinal administration shows 3,000-5,000x greater potency than morphine on hot plate, tail flick, and writhing tests. Activity is naloxone-reversible and shows cross-tolerance with morphine. Banned by horse racing authorities due to illicit use as a performance-enhancing analgesic in racehorses.
Effects
NEUROLOGICAL/PAIN: Primary and essentially sole application. One of the most potent naturally occurring mu-opioid receptor (MOR) agonists ever discovered — 30-40x more potent than morphine by weight, up to 2,170x more potent when delivered directly to the CNS. Binding affinity: Kd ~0.46 nM (100-fold higher than morphine). Spinal administration shows 3,000-5,000x greater potency than morphine on standard pain tests (hot plate, tail flick, writhing). The D-alanine at position 2 is the key: D-amino acids are almost never found in animal peptides, and this configuration (1) provides extreme resistance to peptidase degradation, and (2) is critical for MOR binding and selectivity. Activates two MOR subtypes — both high-affinity and low-affinity mu receptors. Activity is completely naloxone-reversible and shows cross-tolerance with morphine (confirming opioid mechanism). Produces complete analgesia, catalepsy, and respiratory depression at sufficient doses (typical opioid agonist profile). No significant activity at delta or kappa opioid receptors — highly mu-selective. CARDIOVASCULAR: Opioid-related bradycardia and hypotension at analgesic doses (typical MOR agonist effect). RESPIRATORY: Respiratory depression — dose-limiting and potentially lethal side effect shared with all MOR agonists. GI: Slows GI motility (opioid-induced constipation). ENDOCRINE: Suppresses GnRH, LH, testosterone at analgesic doses (opioid-induced hypogonadism). IMMUNE: Immunomodulatory effects typical of opioid agonists — suppresses NK cell activity and lymphocyte proliferation at sustained exposure. ABUSE POTENTIAL: High — full MOR agonist with euphorigenic properties. Schedule I controlled substance in some jurisdictions. Tier 3: Primarily used as a pharmacological research tool, not a clinical agent. Notoriously used illicitly in horse racing as a performance-enhancing analgesic, leading to multiple racing bans worldwide.
Practitioner Guide
IMPORTANT: Dermorphin is NOT used in clinical practice and should NOT be administered to humans. It is included in this encyclopedia for educational completeness because Victory BioLabs offers it as a research product. RESEARCH CONTEXT: Used as a pharmacological tool for studying mu-opioid receptor subtypes, analgesic mechanisms, and opioid pharmacology. Its extreme potency and selectivity make it invaluable for receptor binding studies and structure-activity relationship (SAR) research. LEGAL STATUS: Controlled substance in many jurisdictions. Banned in equine sports worldwide. Possession without research authorization may be illegal. RISKS: Full MOR agonist — carries all risks of opioid analgesics including respiratory depression (potentially fatal), dependence, tolerance, withdrawal, constipation, and endocrine suppression. Extreme potency means dosing errors carry life-threatening risk. NO CLINICAL PROTOCOL EXISTS. This peptide is provided for research use only. STORAGE: Lyophilized — store at -20°C for long-term stability. PATIENT EDUCATION: This is a research-only compound from frog skin. It is one of the most potent painkillers known to exist in nature but is too dangerous for clinical use without extensive safety studies. It is NOT a treatment for pain. If you are dealing with chronic pain, discuss evidence-based options with your physician.
Research Summary
TIER 1 (Gold Standard): Erspamer et al., 1981 — Discovery and characterization of dermorphin from Phyllomedusa skin (original discovery paper). Broccardo et al., 1981 — Pharmacological profile (PNAS, PMID: 7203689). Negri et al., 1992 — Dermorphin-related peptides activate two MOR subtypes (PNAS, PMID: 1323842). Basso et al., 1986 — Spinal action showing 3,000-5,000x potency vs. morphine (Brain Research, PMID: 2877713). TIER 2 (Strong): Lazarus et al., 2009 — Dermorphin-based affinity labels with subnanomolar MOR affinity (PMC2788677). Characterization of tritiated dermorphin binding to mu receptors in rat brain (PMID: 2161761). Extensive opioid pharmacology literature using dermorphin as a reference ligand. TIER 3 (Moderate): Horse racing regulatory investigations documenting illicit use. Reviews of natural opioid peptides including dermorphin. KEY FINDINGS: (1) One of the most potent and selective natural MOR agonists known. (2) D-amino acid at position 2 is a natural rarity and the key to its properties. (3) Invaluable research tool. (4) Not suitable for clinical use. (5) Illicit use in animal sports is a significant concern. GAPS: N/A — well-characterized pharmacologically. Not intended for therapeutic development. ACTIVE TRIALS: None.